Aug 20th 2012 - Edison Investment Research today published a report on Allergy Therapeutics (AGY.L, LSE:AGY, LON:AGY) entitled "US Opportunity Beckons". In summary, the report says:
Allergy’s near-term investment case rests on M&A and successfully capitalising on potentially transformative regulatory catalysts. Confirmation of the lift of the FDA clinical hold on Pollinex Quattro (PQ) Grass, in place since 2007, is one of the latter; opening up the significant US allergy immunotherapy (AIT) opportunity. The FDA has also agreed the Phase III PQ Grass protocol, which means the development and regulatory pathway, costs and timelines are now better defined. This should facilitate Allergy’s efforts to secure a US development and commercialisation partner for PQ.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »